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Alzheimer's DiseaseMany different environmental factors (nutrients, pollutants, chemicals, physical activity, lifestyle, physical and
mental stress) can modulate epigenetic markers in the developing and adult organism. Epigenetics, in turn,
can cause and is associated with several neurodegenerative and aging-dependent human diseases. Alzheimer's
disease certainly represents one of the most relevant neurodegenerative disorders due to its incidence and its
huge socio-economic impact. Therefore, it is easy to understand why recent literature focuses on the epigenetic
modifications associated with Alzheimer's disease and other neurodegenerative disorders.
One of the most intriguing and, at the same time, worrying evidence is that even “mild” environmental factors
(such as behavioral or physical stress) as well as the under-threshold exposure to pollutants and chemicals,
can be effective. Finally, even mild nutrients disequilibria can result in long-lasting and functional alterations
of many epigenetic markers, although they don't have an immediate acute effect. Therefore, we will probably
have to re-define the current risk threshold for many factors, molecules and stresses.
Among the many different environmental factors affecting the epigenome, nutrition represents one of the most
investigated fields; the reasons are probably that each person interacts with nutrients and that, in turn, nutrients
can modulate at molecular level the epigenetic biochemical pathways. The role that nutrition can exert in
modulating epigenetic modifications in Alzheimer's disease will be discussed with particular emphasis on the
role of B vitamins and DNA methylation.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
The term “epigenetics” refers to different biological traits that are
responsible for regulation of gene expression through the interaction
with the DNA sequence of a gene. Althoughmany different phenomena
have been included in the epigenetic traits, and no clear definition of
which is epigenetic and which is not exists, it is usually agreed that
the three most relevant epigenetic modifications are DNA methylation,
histone modifications and miRNAs. Histone modifications (acetylation,
methylation, phosphorylation, ubiquitination) and DNA methylation,
together, constitute a higher-level epigenetic modification defined as
chromatin remodeling.
Epigenetic modifications modulate gene expression during several
physiological processes, mainly during embryonic development and
cellular differentiation, although we have been observing an increasingMarsi, 78, 00183 Rome, Italy.number of pathological processes in which epigenetic mechanisms
appear to be involved or even causative (Portela and Esteller, 2010).
2. Epigenetics and neurodegeneration
The first evidences that epigenetic mechanisms, DNAmethylation in
particular, were associated with specific diseases have been given by
studies on tumors (Jones and Buckley, 1990) and on three neurological
diseases: Fragile X, ICF and Rett syndromes (Fuso, 2013). More recently,
several studies have stressed the relationship between epigenetic
alterations and neurodegenerative disorders (Marques et al., 2011). As
a matter of fact, many diseases have multifactorial origin, depending
not only on genetic but also on stochastic and environmental factors.
These diseases are defined “complex disorders” and include, besides
neurodegenerative diseases, cardiovascular disease, cancer, diabetes
and neuropsychiatric diseases. Alzheimer's disease (AD) is the most
common cause of dementia and the most expensive chronic disease,
constituting a huge social and economical problem. AD is a clinical syn-
drome characterized bymemory impairment in the short and long term
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effective therapies and the huge costs indicate AD as one of the highest
social impacts (Zhu and Sano, 2006). Approximately 33.9million people
worldwide have AD and prevalence will increase 3–4 times in the next
40 years.
AD presents as familial and sporadic forms and although different
polymorphisms and risk factors have been associated with onset and
progression of the disease, the precise way by which the environment
contributes to neurodegeneration is still unclear. Increasing evidences
suggest that environmental factors may contribute to neurodegenera-
tion through themodulation of the epigenetic pattern resulting in alter-
ations of gene expression programs. Epigenetics refers to any process
that alters gene activity without changing the primary DNA sequence
and leads to modifications that can be transmitted to daughter cells. It
is a relatively novel area of research that is currently attracting a high
level of interest. During the lifespan of complex organisms, epigenetic
changes can occur as early as embryonic developmental processes and
constitute a fundamental way to regulate the very complex and coordi-
nated gene expression pattern. The idea that epigenetic modifications
are also associated with the aging processes andwith the loss of pheno-
typic plasticity ismore recent. Since aging is themost important risk fac-
tor for sporadic AD, we can infer that deviations from the “healthy”
epigenetic patterns accumulate with aging and in neurodegeneration,
contributing to the etiology of AD and other neurodegenerative disor-
ders (Fuso, 2013).
DNA methylation, which consists in the binding of a methyl group
(–CH3) to the carbon in position 5 of a cytosine moiety, appears to be
frequently involved in the processes associated both with healthy and
diseased aging, particularly in neurological and neurodegenerative
diseases.
The first example has been the fragile X syndrome (Jin andWarren,
2000): a mental retardation syndrome caused by a CGG triplet repeats
expansion in the 5′-untranslated region of the fragile X mental
retardation-1 (FMR1) gene. The CGG repeats result hypermethylated
in affected subjects causing FMR1 gene repression. Also ICF (Immuno-
deficiency, Centromere instability and Facial abnormalities) and Rett
syndromeswere originally related tomethylation since they are charac-
terized by mutations in genes encoding for proteins involved in the
regulation of the DNA methylation homeostasis (Kumar, 2000). Today
we know that DNA methylation alterations can contribute to a large
number of different neurological and neurodegenerative diseases as a
result of differentmechanisms.Many of the diseases associatedwith ab-
errant DNA methylation show methylation-based imprinting alter-
ations; these include Angelman syndrome, Silver–Russell syndrome,
Prader–Willi syndrome and Beckwith–Wiedemann syndrome, schizo-
phrenia and autism (Falls et al., 1999).
In the recent years, it was possible to demonstrate that genomic and
sequence-specific DNA methylation patterns dynamically changes
during the lifespan and are characteristic and distinct between different
brain areas. It has also been demonstrated that epigenetic changes can
contribute to AD onset and course and that specific loci, such as
PSEN1, are demethylated in AD subjects (reviewed in Mastroeni et al.,
2011). In our laboratory, wewere able at demonstrating that PSEN1 ex-
pression can be modulated by modifying the methylation homeostasis,
with consequent alteration of the amyloidogenic pathway, senile
plaques burden and specific cognitive tasks in AD mice as discussed in
detail in the next section (Fuso, 2013; Fuso et al., 2012). Furthermore,
two independent laboratories recently disclosed new specific loci with
differential methylation associated with AD (De Jager et al., 2014;
Lunnon et al., 2014).
All the data collected thus so far about DNAmethylation in AD point
out a central role for this epigenetic modification in the connection
between amyloidogenic, fibrillogenic, inflammatory and oxidative
pathways. All this evidence proves that DNA methylation is involved
in AD-related molecular mechanisms, either as a primary cause or as
a consequence of the disease; epigenetic studies at genomic and atgene-specific levelswill be necessary to further disclose relevant knowl-
edge on the epigenetic role in AD.
3. Environment and epigenetics
Environmental factors are increasingly claimed to be responsible for
neurodegeneration-related modification; a link between environmental
induced epigenetic modification, oxidation, and repair of AD-related
genes, is discussed in depth in a recent review (Coppedè and Migliore,
2010). The evidencewe have been acquiring on the relationship between
environment and epigenetics teaches us that many epigenetic mecha-
nisms are potentially triggered by a plethora of environmental factors.
This observation can also be seen under a slightly different perspective in-
dicating that the modulation of the epigenetic mechanisms actually acts
as a mediator of environmental stimuli. The term “environment” include,
in this case, many external different processes and conditions that come
in contact with the organism. These environmental factors include,
among others: stressors (physical and behavioral), nutritional factors,
pollutants, pesticides, chemicals, metals, physical exercise, mental exer-
cise and lifestyle. All these factors can exert on the organism different bi-
ological effects that could determine or contribute to the onset and
progression of many diseases.
Environmental factors can induce epigenetic changes in the individ-
ual in each period of the life, from the in utero period to the elderly.
However, it appears obvious that these factors are becoming increasing-
ly relevant with respect to the shift from the healthy to the diseased
statuses of an individual with aging, due to the increased likelihood to
encounter environmental insults or to accumulate their effects during
aging. This observation also stresses the relationship between the
environment-related epigenetic changes and the increasing incidence
of AD andother neurodegenerative diseases observed in the last fewde-
cades: the longer the lifespan of an individual, the higher the possibility
to receive epigenetic “hits” leading to diseased aging (Fig. 1).
On the other hand, increasing epidemiological evidence suggests
that maternal environmental exposure and stimuli result in epigenetic
changes occurring early in development and playing an important role
in susceptibility to disease in later life, even if initially silent. Thus, epi-
geneticmodifications provide a potential link between the environment
encountered during critical periods in development (periconceptional
period, gestation, and early postnatal period) and changes in gene ex-
pression that may lead to disease phenotypes (Jang and Serra, 2014).
It is of extreme interest to notice that even apparentlymild environ-
mental factors like behavioral stress or physical exercise (that do not in-
volve the physical contact of the individual with any chemical species),
could result in a long lasting alteration of epigenetic markers leading to
functional phenotypic alterations. This observation should lead us to
reconsider the cutoff normally considered as “risky” for many other
“classical” environmental factors, such as the exposure to chemicals,
pollutants, metals and pesticides. As a matter of fact, epigenetic studies
reveal that exposures to these agents that are normally considered
“under-threshold” could actually induce epigenetic changes.
The epigenetic effect of behavioral stresswas demonstrated by stud-
ies showing that perinatal behavioral stresses in rats were responsible
for altered AVP or BDNF expression, mediated by DNA methylation
(Roth and Sweatt, 2011).
Physical exercise could also modify the epigenetic pathways leading
to healthy or diseased aging, possibly interacting with behavioral
stressors. Physical exercise improves the efficiency of the capillary sys-
tem and increases the oxygen supply to the brain, thus enhancing meta-
bolic activity and oxygen intake in neurons, and increases neurotrophin
levels and resistance to stress. Regular exercise and an active lifestyle dur-
ing adulthood have been associated with reduced risk and protective
effects for mild cognitive impairment and AD. Similarly, studies in animal
models show that moderate physical activity has positive physiological
and cognitive effects that correlate with changes in transcriptional pro-
files possiblymediated by epigeneticmodifications (Kaliman et al., 2011).
Fig. 1. Environmental factors modify aging through epigenetics. Several environmental
factors can affect the metabolism of an individual by inducing epigenetic modifications.
The figure depicts the inherited DNA methylation pattern which can be modified at local
and sequence-specific levels by different (even mild) stressors. The modification of the
inherited methylome (or of the epigenome, in general) can be responsible for the
alteration of the expression of specific (aging-associated) genes, leading to conditions of
diseased aging.
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mental causes of disease, but these studies are often limited bymethod-
ological problems (e.g. lack of sensitivity and specificity in exposure
assessment, confounding association of different environmental fac-
tors). Proposed approaches to improve observational studies of envi-
ronmental associations are Mendelian randomization and the meet-
in-the-middle (MITM) approach (van Veldhoven et al., 2014).
Both genetic and epigenetic responses of organisms to environmen-
tal factors, including chemical exposures, influence adaptation, suscep-
tibility to toxicity and biodiversity. In model organisms, it has been
established that epigenetic alterations, including changes in DNAmeth-
ylation patterns, can create a memory of the received signal. This has
been shown by the analysis of epigenetic differences that develop
between identical twins, discordant for the occurrence of age-related
diseases. Monozygotic twin siblings share the same genotype because
they are derived from the same zygote. Despite the appearance, they
frequently present phenotypic differences, including their susceptibility
to disease. Studies suggest that aging-associated discordance between
monozygotic twins is partly related to epigenetic differences and factors
changing over their lifetime (Mastroeni et al., 2011). The epigenetic drift
occurring during the development probably results from a combination
of stochastic and environmental factors. One example is represented bya study on twins discordant for Lewy Body Dementia that allowed pos-
tulating that epigenetic factors could play a role in Lewy Body pathology
whereas in another work taking advantage of a rare set of monozygotic
twins discordant for AD, it was possible to observe significantly reduced
levels of DNAmethylation in temporal neocortex neuronal nuclei of the
AD twins (Mastroeni et al., 2011). This result stressed the hypothesis
that the effects of life events on AD risk could bemediated by epigenetic
mechanisms, providing amore general potential explanation for ADdis-
cordance despite genetic similarities.
We can conclude that aging is a process characterized by genetic and
epigenetic interactions, where epigenetics has an important function in
determining phenotypic differences. Epigenetics also plays a key role in
the development of diseases associated with aging and helps to explain
the relationship between individual genetic background, environment,
aging, and disease.
The characterization of the epigenetic patterns of an organism and
the study of the changes occurring in this pattern when the organism
undergoes environmental stimuli could bring to the identification of
specific environmental factors encountered during the lifetime. It is rea-
sonable to consider that, in the future, deviation from the “normal”
epigenetic pattern and the ability at modulating epigenetic markers
also at low concentrations should be taken into accountwhen assessing
environmental toxicity and/or safety of specific factors.
Epigenetics may represent amechanistic link between environmen-
tal exposures, or genetics, and many common diseases, or may simply
provide a quantitative biomarker for exposure or disease for areas of ep-
idemiology currently lacking suchmeasures (Bakulski and Fallin, 2014).
This potential is in part reduced by issues related to the many biases
challenged by the complexity and the interconnection characteristics
of studies dealingwith environmental factors. It is actually very difficult
to separate and analyze the effect of single environmental agents; study
design, measurement tools, statistical methods, and biological interpre-
tation must be carefully considered and, hopefully, standardized. As a
matter of fact, the lack of confidence with the studies, performed so
far, related to the epigenetic effects of environmental factors, is due to
the lack of standardized measurements, difficult in-lab reproduction of
in-environment conditions and the presence of confounding interac-
tions between several environmental factors.
4. Focus on nutrition
Great progress has beenmade in recent years to understand various
facets of epigenetics, including themolecularmechanisms of epigenetic
regulation of gene expression.
Nutrition and diet maybe are the main environmental factors
influencing epigenetics and aging and there is growing evidence that epi-
genetic mechanismsmaymediate the effects of nutrients, micronutrients
and even non-nutrient dietary factors, pointing to themas possible causes
for the development of complex diseases (McKay and Mathers, 2011).
Many nutrients have shown possible epigenetic effects. However, due to
the lack of consistent and reliable data onmany of these factors, the pres-
ent discussion will be focused on the four classes of nutrients for which
we have, so far, the most consistent evidences: polyunsaturated fatty
acids, B vitamins and alcohol as well as metal ions and pesticides that
can be consumed with the diet due to the environmental pollution.
The involvement of nutrition, environmental contaminants and
heavy metals in the development of AD is an emerging hypothesis in
the past few years (Bonda et al., 2011; Olde Rikkert et al., 2014). AD pa-
tients are frequently reported to have lower plasma levels of certain nu-
trients and abnormal metabolism of metal ions in the brain, compared
to the healthy controls. Lower concentrations of polyunsaturated fatty
acids (n-6 and n-3 polyunsaturated fatty acids) and antioxidants were
also found in mild AD patients (Olde Rikkert et al., 2014). Because of
their high content in polyunsaturated fatty acids, neuronal membranes
represent a potential target of the damaging effects of oxidative stress.
The decrease of antioxidants levels observed in AD patients could result
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brane components; the alteration of membrane composition has been
suggested to enhance the APP amyloidogenic processing and increase
Aβ production and aggregation in vitro (Grimm et al., 2012).
Different environmental factors (vitamin B deficiency, alcohol,
pesticides and metals), associated with AD risk, appear able to induce
epigenetic changes in the brain. Among the various mechanisms by
which environmental factors could affect the progress of senescence,
two pathways involveDNAmethylation: thefirst is referred to elements
able to modify DNMT activity (arsenic, cadmium, lead and pesti-
cides), whereas the second involves the supply of metabolites of the
S-adenosylmethionine cycle.
It was established that the adventitious uptake and accumulation of
somemetal via nutrient transporters could lead to epigenetic modifica-
tion. Lead (Pb) has been proven to exert neurotoxic effects through
different mechanisms; in the last years it was shown that Pb could
alter the expression of several DNA methyltransferases. Reduction of
DNMT1 expression (the maintenance methyltransferase that copies
the preexisting methylation markers onto the new strand during DNA
replication) was observed in the undifferentiated PC12 cells treated
with high dosage of Pb; this alteration is able to modulate DNAmethyl-
ation patterns and could cause permanentmolecular damage toDNA(Li
et al., 2012). Moreover, Pb could inhibit DNMT3a (a de novo methyl-
transferase that introduces new methylation markers onto DNA) tran-
scription by binding to its promoter (Tsai et al., in press) leading to
the reduction of cytosine methylation in CpG islands within gene pro-
moters. Therefore, an important consequence of Pb exposure could be
the hypomethylation of CpG dinucleotide in the APP promoter leading
to abnormal APP processing (Li et al., 2012).
Another heavy metal that affects DNMT activity is the cadmium
(Cd). Short exposure to Cd reduces DNMT activity resulting in DNA
hypomethylation. In contrast, chronic Cd exposures result in a dose-
dependent increase in cellular DNMT activity and concomitant DNA
hypermethylation (Takiguchi et al., 2003). However, the differential ef-
fect on DNMT activity observed under short and long exposures to Cd is
not well understood. In addition, upregulation of DNMT1 and DNMT3A/
B expression has been correlated to global DNA hypermethylation in
cells chronically exposed to Cd (Jiang et al., 2008). Overall, the data sug-
gest that short exposure to Cd is associatedwith DNA hypomethylation,
whereas chronic exposure is associated with DNA hypermethylation.
The intake of arsenic (As) causes the response of a variety of detox-
ification pathways. Methylation of inorganic As produces different or-
ganic forms that are less toxic than inorganic As (Ye et al., 2012).
In mammals, cellular inorganic As is methylated by the arsenic methyl-
transferase (AS3MT) that utilizes S-adenosylmethionine (SAM) as the
methyl donor (Gebel, 2002). Arsenic is extensively methylated during
its metabolism and for this reason it has been proposed that As
intake may deplete the methyl-donor pool of the cell, leading to
DNA hypomethylation.
While acute toxic effects of pesticides are well known, uncertainties
still remain regarding sub-acute, chronic and long-term effects. For
some pesticides, like dichlorodiphenyltrichloroethane (DDT) or envi-
ronmental endocrine disruptors (EDs), it is ascertained that they can
cause epigenetic perturbations (Shutoh et al., 2009). Pesticides could
act through several epigenetic mechanisms, including DNA methyla-
tion, histone modifications, and microRNA (miRNA) expression alter-
ation (Baccarelli and Bollati, 2009). Further studies are warranted to
evaluate if epigenetic modifications may have the role of a causal link
between pesticide exposure and health effects, or rather be a sensitive
marker of exposure.
Other metabolites that could impact disease states by binding to
transcription factors and/or modifying chromatin structure, thereby al-
tering gene expression patterns, are those generated during ethanol
metabolism. It was shown that chronic alcohol consumption leads to
either substantial DNA hypomethylation as a result of significant reduc-
tion in tissue SAM levels or histone modification. In fact, alcoholconsumption is able to perturb SAM metabolism and induce degrada-
tion of DNMTs (Chen et al., 2013; Mukhopadhyay et al., 2013).
The group B vitamins (folate, B6 and B12) play important roles in
SAM metabolism. After methyl group transfer, SAM is converted in
S-adenosylhomocysteine (SAH), which is a strong competitive inhibitor
of methyltransferases (Lu, 2000). Then, SAH is hydrolyzed to homocys-
teine (HCY) and adenosine by the enzyme S-adenosylhomocysteine hy-
drolase (SAHH); this reaction proceeds in the hydrolytic direction only
if HCY and adenosine are efficiently removed. HCY can be, in turn,
converted into either glutathione (GSH), an important antioxidant, via
series of intermediate steps requiring vitamin B6 as a cofactor, ormethi-
onine. The re-methylation of HCY occurs through the transfer of ameth-
yl group from 5-methyltetrahydrofolate by methionine synthase, that
utilizes folate and vitamin B12 as cofactors. Deficiency of these vitamins
hampers the conversion of HCY to methionine or cystathionine; there-
fore, HCY reverts to SAH resulting in altered methylation metabolism
(Fuso et al., 2005). In the last few years, it has been demonstrated that
there is a correlation between B vitamin deficiency and DNA methyla-
tion. In our laboratory we demonstrated that a transgenic mouse
model of AD, the TgCRND8mice, treated with a diet deficient of vitamin
B12, B6 and folate showed a decrease of SAM/SAH ratio leading to im-
paired methylation potential, DNMTs inhibition and DNA demethylase
stimulation, PSEN1 promoter hypomethylation, PSEN1 overexpression,
increased amyloid processing and deposition in senile plaques and,
finally, cognitive impairment. The supplementation with SAM was able
to restore control-like conditions in AD mice or even to partially revert
the Alzheimer-like phenotype (Fuso et al., 2012). Other laboratories
have confirmed the role of B vitamins and DNAmethylation in molecular
mechanisms related to AD onset and progression (Mastroeni et al., 2011).
An alternative approach adopted in other laboratories was to control the
hyperhomocysteinemia with B vitamin supplementation. Results from
observational and intervention studies showed either increased risk of
cognitive decline associated with higher levels of folate intake (Morris
et al., 2005) or null or inconclusive results on cognitive decline (Wald
et al., 2010). The reason for these inconclusive results could be due to
the length of follow-up (median follow-up time b1 year), which may
not provide the time needed for vitamin B supplementation to exert a
protective effect. On the contrary, a randomized controlled study on el-
derly subjects with mild cognitive impairment showed that B-vitamin
treatment was able to reduce the cerebral atrophy in graymatter regions
specifically vulnerable to the AD process, including the medial temporal
lobe (Douaud et al., 2013).
5. Conclusions
The concept that many different environmental stimuli can interact
with the genome of an organism not just at genomic level (inducing
mutations) but also at epigenetic level and that this interaction can
lead to a diseased status is finallywidely accepted. Nevertheless, the en-
vironment–epigenetic-disease connection still deserves more intense
and more rigorous researches in order to achieve clear data and to be
able to apply this knowledge to the prevention and the therapy of relat-
ed diseases. One important aspect, in this sense, is represented by the
availability of “epigenetic drugs” (in some case already in use in the
clinical practice) and by the specific characteristic of the epigenetic
modification to be (potentially) reversible.
The neurodegenerative diseases represent one of themost clear, rel-
evant and studied examples of the environmental-associated and
epigenetic-related causes of the disease; the primary reason seems to
be ascribable to the increasing length of the lifespan that favorsmultiple
environmental “insults”. On the other hand, the slow development of
these diseases, together with the difficulties in studying the human
brain, constitutes a major drawback for the neuroepigeneticists. Anoth-
er major problem is represented by the difficulty in discriminating
between the effect of concurrent and interacting environmental factors
of different natures on the human health. Finally, a thirdmajor hindrance
12 V. Nicolia et al. / Experimental Gerontology 68 (2015) 8–12resides on the “silent” period often existing between the environmental
insult and the manifestation of the “unhealthy” effects on the organism,
together with our nescience of the effective dosage at which the environ-
mental factors exert these effects. Nonetheless, a major value of these
kinds of studies will be the definition of the exact detrimental dosage of
certain environmental factors for which only the toxic acute exposure is
known so far.
The characterization of experimental models and the application of
unbiased epigenomic approaches will be warranted to accomplish the
challenging study of the epigenetic alterations induced by environmental
factors.
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